Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

PLX Relative to the S&P 500

PLX Relative to the Sector

% of Revenue Generated in Each Quarter

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the Protalix BioTherapeutics, Inc. (AMEX:PLX) seasonal charts above shows that a Buy Date of December 21 and a Sell Date of April 21 has resulted in a geometric average return of 14.97% above the benchmark rate of the S&P 500 Total Return Index over the past 20 years. This seasonal timeframe has shown positive results compared to the benchmark in 13 of those periods. This is a good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 20 years by an average of 34.46% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company’s products also treat diseases like Fabry disease and cystic fibrosis. The company’s primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company’s pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.

To download PLX seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: PLX